These findings suggest that EDIL3 functions as an important mediator of pathological vascular permeability and angiogenesis in the subchondral bone during OA progression. Targeting EDIL3 to restore subchondral bone microenvironment homeostasis may represent a novel therapeutic strategy for OA management.
Ma et al. (Mon,) studied this question.